Comparative Pharmacology
Head-to-head clinical analysis: LEDERCILLIN VK versus OMNIPEN N.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEDERCILLIN VK versus OMNIPEN N.
LEDERCILLIN VK vs OMNIPEN-N
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It is bactericidal against susceptible organisms during the active growth phase.
Omnipen-N (ampicillin sodium) is a beta-lactam antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), thereby interfering with transpeptidation and resulting in cell lysis.
250-500 mg orally every 6 hours for mild to moderate infections; 500 mg orally every 6 hours for severe infections.
250-500 mg orally every 6 hours for adults; for severe infections, up to 1 g every 6 hours.
None Documented
None Documented
Terminal elimination half-life is 0.5 hours (range 0.4–0.6 hours) in adults with normal renal function. In severe renal impairment (CrCl <10 mL/min), half-life extends to ~4 hours.
30-60 minutes (normal renal function); prolonged to 7-10 hours in severe renal impairment (CrCl <10 mL/min).
Renal elimination predominantly via tubular secretion of unchanged drug (>90% of absorbed dose). Approximately 20-40% of an oral dose is recovered in urine as unchanged penicillin V. Biliary excretion accounts for <1% of elimination; fecal elimination is negligible.
Primarily renal (80-90% unchanged via tubular secretion); minor biliary/fecal (<10%).
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic